No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDNA240517C12500
- 3.10
- +0.10+3.33%
15min DelayClose May 14 16:00 ET
3.10High3.10Low
3.10Open3.00Pre Close1 Volume78 Open Interest12.50Strike Price310.00Turnover0.00%IV-0.43%PremiumMay 17, 2024Expiry Date2.74Intrinsic Value100Multiplier3DDays to Expiry0.36Time Value100Contract SizeAmericanOptions Type--Delta--Gamma5.70Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Buy Rating Justified: CareDx's Strong Financial Performance and Market Potential
Raymond James Downgrades CareDx to Market Perform From Outperform
Raymond James Downgrades CareDx to Market Perform From Outperform.
Express News | CareDx Inc : Raymond James Cuts to Market Perform From Outperform
Navigating 5 Analyst Ratings For CareDx
Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:CDNA), offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent ratings, showcasing
Express News | Raymond James Downgrades CareDx to Market Perform
CareDx Cut to Market Perform by Raymond James Over Valuation
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more